IQVIA Holdings Inc. (0JDM.L)
USD 157.19
(-6.74%)
USD 157.19
(-6.74%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 12.95 Billion USD | 0.75% |
| 2022 | 12.85 Billion USD | 4.15% |
| 2021 | 12.34 Billion USD | -3.2% |
| 2020 | 12.75 Billion USD | 6.82% |
| 2019 | 11.94 Billion USD | 9.48% |
| 2018 | 10.9 Billion USD | 7.76% |
| 2017 | 10.12 Billion USD | 42.4% |
| 2016 | 7.1 Billion USD | 193.8% |
| 2015 | 2.41 Billion USD | 5.53% |
| 2014 | 2.29 Billion USD | 12.62% |
| 2013 | 2.03 Billion USD | -13.97% |
| 2012 | 2.36 Billion USD | 21.24% |
| 2011 | 1.95 Billion USD | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 12.81 Billion USD | -1.05% |
| 2024 Q3 | 12.29 Billion USD | 1.67% |
| 2024 Q2 | 12.09 Billion USD | -5.68% |
| 2023 Q2 | 12.67 Billion USD | 4.86% |
| 2023 Q4 | 12.95 Billion USD | 3.32% |
| 2023 FY | 12.95 Billion USD | 0.75% |
| 2023 Q3 | 12.53 Billion USD | -1.07% |
| 2023 Q1 | 12.08 Billion USD | -6.0% |
| 2022 FY | 12.85 Billion USD | 4.15% |
| 2022 Q3 | 12.5 Billion USD | -3.09% |
| 2022 Q1 | 12.85 Billion USD | 4.13% |
| 2022 Q2 | 12.9 Billion USD | 0.33% |
| 2022 Q4 | 12.85 Billion USD | 2.86% |
| 2021 Q1 | 12.43 Billion USD | -2.48% |
| 2021 FY | 12.34 Billion USD | -3.2% |
| 2021 Q2 | 12.48 Billion USD | 0.37% |
| 2021 Q4 | 12.34 Billion USD | -0.46% |
| 2021 Q3 | 12.4 Billion USD | -0.65% |
| 2020 Q3 | 12.58 Billion USD | 1.74% |
| 2020 Q4 | 12.75 Billion USD | 1.37% |
| 2020 Q1 | 12.26 Billion USD | 2.67% |
| 2020 Q2 | 12.36 Billion USD | 0.87% |
| 2020 FY | 12.75 Billion USD | 6.82% |
| 2019 Q4 | 11.94 Billion USD | 0.88% |
| 2019 Q3 | 11.83 Billion USD | 1.2% |
| 2019 Q2 | 11.69 Billion USD | 0.94% |
| 2019 Q1 | 11.58 Billion USD | 6.24% |
| 2019 FY | 11.94 Billion USD | 9.48% |
| 2018 Q1 | 10.34 Billion USD | 2.17% |
| 2018 FY | 10.9 Billion USD | 7.76% |
| 2018 Q4 | 10.9 Billion USD | 3.7% |
| 2018 Q3 | 10.51 Billion USD | -1.03% |
| 2018 Q2 | 10.62 Billion USD | 2.76% |
| 2017 FY | 10.12 Billion USD | 42.4% |
| 2017 Q1 | 8.25 Billion USD | 16.12% |
| 2017 Q3 | 9.65 Billion USD | 8.95% |
| 2017 Q4 | 10.12 Billion USD | 4.88% |
| 2017 Q2 | 8.85 Billion USD | 7.32% |
| 2016 Q1 | 2.4 Billion USD | -0.44% |
| 2016 FY | 7.1 Billion USD | 193.8% |
| 2016 Q4 | 7.1 Billion USD | 197.77% |
| 2016 Q3 | 2.38 Billion USD | -0.45% |
| 2016 Q2 | 2.39 Billion USD | -0.45% |
| 2015 Q2 | 2.44 Billion USD | 6.68% |
| 2015 Q1 | 2.28 Billion USD | -0.19% |
| 2015 FY | 2.41 Billion USD | 5.53% |
| 2015 Q4 | 2.41 Billion USD | -0.44% |
| 2015 Q3 | 2.43 Billion USD | -0.45% |
| 2014 Q4 | 2.29 Billion USD | 13.34% |
| 2014 Q2 | 2.02 Billion USD | -0.21% |
| 2014 Q1 | 2.03 Billion USD | -0.21% |
| 2014 FY | 2.29 Billion USD | 12.62% |
| 2014 Q3 | 2.02 Billion USD | -0.21% |
| 2013 Q1 | 2.35 Billion USD | -0.49% |
| 2013 Q2 | 2.04 Billion USD | -13.15% |
| 2013 Q3 | 2.04 Billion USD | -0.15% |
| 2013 FY | 2.03 Billion USD | -13.97% |
| 2013 Q4 | 2.03 Billion USD | -0.32% |
| 2012 FY | 2.36 Billion USD | 21.24% |
| 2012 Q4 | 2.36 Billion USD | 0.0% |
| 2011 FY | 1.95 Billion USD | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| uniQure N.V. | 130.06 Million USD | -9860.404% |
| Agios Pharmaceuticals, Inc. | 56.98 Million USD | -22632.856% |
| Amicus Therapeutics, Inc. | 387.85 Million USD | -3240.14% |
| Atara Biotherapeutics, Inc. | 45.69 Million USD | -28252.264% |
| bluebird bio, Inc. | 224.41 Million USD | -5672.684% |
| Cara Therapeutics, Inc. | 37.07 Million USD | -34838.914% |
| Imunon, Inc. | 1.13 Million USD | -1137008.716% |
| Editas Medicine, Inc. | 24.37 Million USD | -53055.26% |
| Mettler-Toledo International Inc. | 1.97 Billion USD | -555.767% |
| Myriad Genetics, Inc. | 130.9 Million USD | -9796.868% |
| Neurocrine Biosciences, Inc. | 258.3 Million USD | -4915.486% |
| Supernus Pharmaceuticals, Inc. | 33.19 Million USD | -38925.786% |
| Verastem, Inc. | 40.08 Million USD | -32218.016% |
| Walgreens Boots Alliance, Inc. | 8.04 Billion USD | -61.052% |
| Waters Corporation | 2.3 Billion USD | -461.914% |
| Thermo Fisher Scientific Inc. | 31.3 Billion USD | 58.621% |
| Biogen Inc. | 7.18 Billion USD | -80.226% |
| Nektar Therapeutics | 112.62 Million USD | -11402.775% |
| Perrigo Company plc | 3.63 Billion USD | -256.612% |
| Dynavax Technologies Corporation | 252.41 Million USD | -5032.36% |
| Illumina, Inc. | 1.48 Billion USD | -770.047% |
| Corbus Pharmaceuticals Holdings, Inc. | 3.23 Million USD | -399914.698% |
| Iovance Biotherapeutics, Inc. | 1 Million USD | -1295400.0% |
| Heron Therapeutics, Inc. | 173.75 Million USD | -7355.986% |
| Unity Biotechnology, Inc. | 23.53 Million USD | -54936.323% |
| BioMarin Pharmaceutical Inc. | 593.09 Million USD | -2084.304% |
| Sangamo Therapeutics, Inc. | 33.51 Million USD | -38554.334% |
| Evolus, Inc. | 120.35 Million USD | -10663.632% |
| Adicet Bio, Inc. | 17.7 Million USD | -73079.687% |
| Aclaris Therapeutics, Inc. | 3.07 Million USD | -421337.866% |
| Regeneron Pharmaceuticals, Inc. | 2.7 Billion USD | -379.3% |
| Esperion Therapeutics, Inc. | 501.54 Million USD | -2483.013% |
| FibroGen, Inc. | 89.69 Million USD | -14343.069% |
| Agilent Technologies, Inc. | 2.73 Billion USD | -373.675% |
| OPKO Health, Inc. | 222.03 Million USD | -5734.692% |
| Homology Medicines, Inc. | 43.17 Million USD | -29905.095% |
| Geron Corporation | 35.05 Million USD | -36860.429% |
| Alnylam Pharmaceuticals, Inc. | 2.34 Billion USD | -452.918% |
| Exelixis, Inc. | 189.94 Million USD | -6720.431% |
| Viking Therapeutics, Inc. | 936 Thousand USD | -1383981.197% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 96.74 Million USD | -13290.596% |
| Zoetis Inc. | 6.56 Billion USD | -97.364% |
| Axsome Therapeutics, Inc. | 178.07 Million USD | -7175.229% |
| Abeona Therapeutics Inc. | 4.4 Million USD | -294198.046% |
| Vertex Pharmaceuticals Incorporated | 724.7 Million USD | -1687.636% |
| Kala Pharmaceuticals, Inc. | 34.19 Million USD | -37791.196% |
| Ionis Pharmaceuticals, Inc. | 1.4 Billion USD | -825.109% |
| Sarepta Therapeutics, Inc. | 1.13 Billion USD | -1043.914% |
| Corcept Therapeutics Incorporated | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 1.49 Billion USD | -764.1% |
| Blueprint Medicines Corporation | 610.96 Million USD | -2020.426% |
| Insmed Incorporated | 1.19 Billion USD | -985.598% |
| TG Therapeutics, Inc. | 100.11 Million USD | -12839.731% |
| Incyte Corporation | 29.16 Million USD | -44324.251% |
| Emergent BioSolutions Inc. | 446.5 Million USD | -2801.456% |